Abstract:Young injection drug users (IDUs) are at risk for acquiring blood-borne diseases like HIV and Hepatitis C. Little is known about the population prevalence of young IDUs. We (1) estimate annual population prevalence rates of young IDUs (aged 15–29) per 10,000 in 95 large U.S. metropolitan statistical areas (MSAs) from 1992 to 2002; (2) assess the validity of these estimates; and (3) explore whether injection drug use among youth in these MSAs began to rise after HAART was discovered. A linear mixed model (LMM) … Show more
“…Finally, it is important to recognize that HIV prevention efforts may also be geared toward the subset of non-injecting drug users who are at risk for transition to injection [99]. Injection drug use among adolescents and young adults in the United States may be increasing [32, 100] and some have suggested that the recent trends in prescription opioid use may signal increasing transitions to injection drug use [101, 102]. Risk behaviors and the injection and sex risk networks of this new generation of IDUs will affect the future course of the HIV epidemic.…”
This study compared HIV sero-prevalence and risk behaviors between younger and older injecting drug users (IDUs). IDUs aged ≥18 years were interviewed for the 2009 National HIV Behavioral Surveillance System. Using GEE regression, we assessed characteristics of younger (18–29 years) and older (≥30 years) IDUs, and factors associated with past 12-month receptive syringe sharing and unprotected sex (vaginal/anal). Of 10,090 participants, 10 % were younger. HIV sero-prevalence was lower among younger than older IDUs (4 vs. 10 %, p = 0.001). Younger IDUs were more likely (p ≤ 0.002) to be non-black race/ethnicity, report higher household income, homelessness, being arrested and to engage in receptive syringe sharing and unprotected sex. In multivariable models, age remained associated (p < 0.001) with receptive syringe sharing (aPR = 1.14, 95 % CI1.07–1.22) and unprotected sex (aPR = 1.10, 95 % CI1.06–1.14). Although younger IDUs had lower HIV prevalence, their behaviors place them at increased risk of HIV infection and could lead to a rapid spread in this susceptible population.
“…Finally, it is important to recognize that HIV prevention efforts may also be geared toward the subset of non-injecting drug users who are at risk for transition to injection [99]. Injection drug use among adolescents and young adults in the United States may be increasing [32, 100] and some have suggested that the recent trends in prescription opioid use may signal increasing transitions to injection drug use [101, 102]. Risk behaviors and the injection and sex risk networks of this new generation of IDUs will affect the future course of the HIV epidemic.…”
This study compared HIV sero-prevalence and risk behaviors between younger and older injecting drug users (IDUs). IDUs aged ≥18 years were interviewed for the 2009 National HIV Behavioral Surveillance System. Using GEE regression, we assessed characteristics of younger (18–29 years) and older (≥30 years) IDUs, and factors associated with past 12-month receptive syringe sharing and unprotected sex (vaginal/anal). Of 10,090 participants, 10 % were younger. HIV sero-prevalence was lower among younger than older IDUs (4 vs. 10 %, p = 0.001). Younger IDUs were more likely (p ≤ 0.002) to be non-black race/ethnicity, report higher household income, homelessness, being arrested and to engage in receptive syringe sharing and unprotected sex. In multivariable models, age remained associated (p < 0.001) with receptive syringe sharing (aPR = 1.14, 95 % CI1.07–1.22) and unprotected sex (aPR = 1.10, 95 % CI1.06–1.14). Although younger IDUs had lower HIV prevalence, their behaviors place them at increased risk of HIV infection and could lead to a rapid spread in this susceptible population.
“…Recent trends show that although both HIV (Broz et al, 2014; Centers for Disease Control and Prevention, 2009) and HCV (Amon et al, 2008) prevalence have steadily declined among older PWID, high-incidence of HCV infection (Page et al, 2009; Zibbell et al, 2015) and HCV outbreaks among younger PWID (Centers for Disease Control and Prevention, 2011; Leuchner et al, 2008) are occurring. In addition, IDU has been steadily increasing among youths (Chatterjee et al, 2011; Tempalski et al, 2013), and high levels of risky injection and sex behaviors continue to be reported in this group (Broz et al, 2014; Hahn et al, 2010; Rondinelli et al, 2009). …”
Background
Little is known about young persons who inject drugs (PWID), who are increasingly from suburban communities and predominantly non-Hispanic white.
Methods
We conducted a cross-sectional personal network (egocentric) and geographic study of young PWID and their drug-using, sexual, and support network members in 2012-13 in metropolitan Chicago, Illinois, U.S.
Results
We enrolled 164 young (median age=26), mostly male (65%), non-Hispanic white PWID (71%), with a self-reported HCV prevalence of 13%. Many (59%) reported multiple residences (i.e., were transient) in the past year, 45% of whom reported living in both urban and suburban places (i.e., were cross-over transients). In multivariable analyses that adjusted for participant and network member characteristics, (1) large injection networks were more common among homeless participants; and (2) syringe sharing was (a) highest among cross-over transients compared to suburban (OR = 4.19 95% CI 1.69 – 10.35) and urban only residents (OR = 2.91 95% CI 1.06 – 8.03), (b) higher among HCV-unknown compared HCV-negative participants (OR = 4.62 95% CI 1.69-10.35), (c) more likely with network members who were cross-over transients compared to urban (OR = 4.94, 95% CI 2.17 – 11.23) and (d) less likely with network members with HCV-unknown compared to HCV-negative status (OR = 0.4 95% CI 0.19 – 0.84).
Conclusions
We identified homelessness as a significant risk factor for large networks and cross-over transience as a significant risk factor for syringe sharing. Further research is needed to understand the role of geographic factors promoting higher risk among these crossover transient PWID.
“…9 The increase in HCV infections among youth and young adults may be attributable to prescription opioid misuse and injection drug use, which has also been increasing in similar age groups. [10][11][12][13] It has been demonstrated that some prescription opioid abusers transition to injection drug use, 6,[14][15][16][17] putting them at increased risk for acquiring blood-borne infections such as HCV and HIV.…”
Increases in prescription opioid misuse, injection drug use, and hepatitis C infections have been reported among youth and young adults in the USA, particularly in rural and suburban areas. To better understand these trends in New York City and to characterize demographics and risk factors among a population who, by virtue of their age, are more likely to be recently infected with hepatitis C, we analyzed routine hepatitis C surveillance data from 2009 to 2013 and investigated a sample of persons 30 and younger newly reported with hepatitis C in 2013. Between 2009 and 2013, 4811 persons 30 and younger were newly reported to the New York City Department of Health and Mental Hygiene with hepatitis C. There were high rates of hepatitis C among persons 30 and younger in several neighborhoods that did not have high rates of hepatitis C among older people. Among 402 hepatitis C cases 30 and younger investigated in 2013, the largest proportion (44 %) were white, non-Hispanic, and the most commonly reported risk factor for hepatitis C was injection drug use, mostly heroin. Hepatitis C prevention and harm reduction efforts in NYC focused on young people should target these populations, and surveillance for hepatitis C among young people should be a priority in urban as well as rural and suburban settings.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.